Secondary cytoreductive surgery for recurrent ovarian cancer : A prospective study

摘要: Background. The prognosis for patients with recurrent epithelial ovarian cancer is poor. Most are treated salvage chemotherapy. role of secondary cytoreductive surgery controversial. Hence, this prospective study was undertaken to determine the feasibility and benefit before administration chemotherapy. Methods. Between 1990 1994, 36 underwent surgical cytoreduction. All had prior primary surgery, platin-based chemotherapy, relapsed at least 6 months after completion treatment. goal excision all macroscopic disease initiation chemotherapy or radiation therapy. Statistical analysis which clinical pathologic variables influenced complete as well morbidity, mortality, survival benefit, quality life resulting from surgery. Results. Thirty (83.0%) excisions. probability a by Gynecologic Oncology Group (GOG) performance status (0–2 vs. 3, P = 0.05) size largest tumor deposit ( 10 cm, 0.03). Eleven (30.1%) experienced morbidity 1 (2.8%) died postoperatively. Of 27 symptomatic 3 follow-up, 26 (96.2%) resolution improvement their symptoms. 25 followed postoperatively, 23 (92.0%) GOG 0 1. Survival adversely (P 0.02), preoperative 0.01), brief free interval treatment 0.01). median extended completely resected radiation, compared those residual remaining (43 5 months, 0.03). Conclusions. Complete technically feasible has an acceptable operative complication rate. significantly improved having resection. Subsequent relief symptoms excellent. Cancer 1995; 76:1606–14.